---
id: 206
title: Acute Pyelonephritis
category: clinical_syndromes
subcategory: urinary_tract
tags: [pyelonephritis, UTI, ceftriaxone, fluoroquinolone, ESBL, bacteremia]
difficulty: medium
---

## Question

How is acute pyelonephritis managed? Use **"Uncomplicated: Cipro/Ceftriaxone × 7d, Complicated: IV × 14d, Bacteremia: 10-14d"** framework.

## Answer

### **Clinical Presentation:**

**Symptoms:**
- **Fever, chills** (≥38°C)
- **Flank pain, costovertebral angle (CVA) tenderness**
- **Nausea, vomiting**
- **Lower urinary symptoms** (dysuria, frequency, urgency) - may be absent

**Labs:**
- **Pyuria** (>10 WBC/HPF)
- **Bacteriuria** (>10⁵ CFU/mL)
- **WBC casts** (if present, pathognomonic)
- **Leukocytosis, ↑CRP**

**Blood Cultures:**
- **Positive in 10-30%** (bacteremia common)

### **Classification:**

**Uncomplicated:**
- **Premenopausal, non-pregnant women**
- **No structural/functional urinary tract abnormalities**
- **No recent instrumentation, antibiotics**
- **Immunocompetent**

**Complicated:**
- **Men** (all considered complicated)
- **Pregnancy**
- **Structural abnormalities** (obstruction, stones, neurogenic bladder)
- **Recent instrumentation** (catheter, cystoscopy)
- **Immunocompromised** (diabetes, transplant, neutropenia)
- **Recent antibiotics** (MDR risk)
- **Healthcare-associated**

### **Microbiology:**

**Uncomplicated:**
- ***E. coli*** (75-95%)
- ***Klebsiella pneumoniae*, *Proteus mirabilis*** (5-15%)

**Complicated:**
- ***E. coli*** (still most common, but lower %)
- **MDROs:** ESBL-producing Enterobacterales, *Pseudomonas aeruginosa*, *Enterococcus*
- ***Candida* species** (if prolonged catheter, ICU, immunosuppressed)

### **Treatment:**

**Uncomplicated (Outpatient):**

**Empiric (7 Days Total):**
- **Ciprofloxacin 500mg PO BID** OR **levofloxacin 750mg PO daily × 7 days**
  - **If local *E. coli* fluoroquinolone resistance <10%**
- **Ceftriaxone 1-2g IV/IM daily × 1** → **then oral step-down** (cefpodoxime, TMP-SMX, fluoroquinolone based on susceptibilities) × 7 days total

**Alternative:**
- **TMP-SMX DS PO BID × 7-14 days** (if susceptible, but higher resistance rates)

**Narrow Based on Cultures:**
- **Switch to oral** when afebrile × 24-48h + clinically improved

**Complicated (Inpatient IV Initially):**

**Empiric:**
- **Ceftriaxone 1-2g IV daily** OR **cefepime 1-2g IV q8-12h**
- **If septic/unstable:** Pip-tazo 3.375-4.5g IV q6-8h OR carbapenem (meropenem 1g IV q8h)
- **If ESBL risk:** Ertapenem 1g IV daily OR meropenem 1g IV q8h

**Duration:**
- **10-14 days** (IV until afebrile × 24-48h, then oral step-down)

**Bacteremia:**
- **10-14 days** (total)
- **Repeat blood cultures** (ensure clearance)

### **Special Situations:**

**Pregnancy:**
- **Hospitalize** (higher risk of complications)
- **Ceftriaxone 1-2g IV daily** × 7-14 days
- **Avoid:** Fluoroquinolones (teratogenic), TMP-SMX (1st/3rd trimester), nitrofurantoin (term)

**Men:**
- **Always complicated**
- **10-14 days** (higher relapse rate)
- **Consider prostatitis** (if prolonged symptoms, may need 4-6 weeks)

**Urinary Obstruction:**
- **Urgent relief** (percutaneous nephrostomy, ureteral stent)
- **Antibiotics + drainage**

**Emphysematous Pyelonephritis:**
- **Gas-forming infection** (diabetes, *E. coli*, *Klebsiella*)
- **CT shows gas in renal parenchyma**
- **High mortality** (10-20%)
- **Treatment:** IV antibiotics + percutaneous drainage OR nephrectomy (if severe)

**Renal/Perinephric Abscess:**
- **If abscess >3 cm:** Percutaneous drainage + antibiotics × 2-3 weeks
- **Hematogenous** (*S. aureus*) vs. ascending (*E. coli*)

**ESBL *E. coli* / *Klebsiella*:**
- **Risk factors:** Recent antibiotics (especially cephalosporins, fluoroquinolones), healthcare exposure, travel to high-prevalence areas
- **Treatment:** Ertapenem 1g IV daily OR meropenem 1g IV q8h

### **Follow-Up:**

**Repeat Imaging:**
- **NOT routinely needed** (if uncomplicated, responds to treatment)
- **Indications:** Persistent symptoms >72h, recurrent infection, concern for obstruction/abscess

**Urine Culture:**
- **Test of cure NOT needed** if asymptomatic
- **Repeat if:** Persistent symptoms, high-risk (pregnancy, urologic abnormality)

### **Complications:**

**Acute:**
- **Sepsis/septic shock** (10-20%)
- **Acute kidney injury**
- **Bacteremia** (10-30%)

**Chronic:**
- **Renal scarring** (especially recurrent infections)
- **Recurrent pyelonephritis**

## Key Points

### **Uncomplicated = Outpatient 7 Days:**
- **Fluoroquinolone** (cipro/levo) × 7 days
- OR **ceftriaxone 1-2g IV × 1** → oral step-down × 7 days total

### **Complicated = Inpatient 10-14 Days:**
- **IV initially** (ceftriaxone, cefepime, pip-tazo, carbapenem)
- **Switch to oral** when afebrile × 24-48h + improved

### **Bacteremia Common:**
- **10-30%** have positive blood cultures
- **Repeat cultures** to ensure clearance
- **Duration:** 10-14 days

### **Men = Always Complicated:**
- **10-14 days** treatment
- **Consider prostatitis** (may need longer)

### **ESBL Risk:**
- **Recent antibiotics, healthcare exposure**
- **Carbapenem** (ertapenem, meropenem)

### **Clinical Pearls:**
- **Uncomplicated:** Ciprofloxacin 500mg BID × 7 days OR ceftriaxone IV × 1 → oral × 7 days
- **Complicated:** IV (ceftriaxone, cefepime) × 10-14 days
- **Bacteremia:** 10-14 days, repeat cultures
- **Men:** Always complicated (10-14 days)
- **ESBL risk:** Carbapenem (ertapenem, meropenem)

## Sources

- [IDSA: Urinary Tract Infection Guidelines 2024]
- [CID: Pyelonephritis Management 2024]

## Media

N/A
